Zak Mir talks to Tim McCarthy, CEO ImmuPharma, in the wake of a series of announcements this year which have transformed the outlook for the AIM listed (LSE:IMM) evolving speciality pharma company.
Interview: Tim McCarthy, CEO ImmuPharma
Your stock market edge
Sign up to Zaks Stock Market News Email
